Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension
National Heart and Lung Institute of Imperial College London Harefield Hospital Middlesex, UK
revised 11 February 1997; accepted 24 February 1997.
Correspondence: Professor Sir M. Yacoub, Department of Cardiothoracic Surgery and Transplant Medicine, Harefield Hospital, Harefield, Middlesex UB9 6JH, U.K.
Abstract
AIMS: To investigate the response to inhaled prostacyclin in patients with primary and secondary pulmonary hypertension and to compare its effects to those of intravenous prostacyclin and inhaled nitric oxide.
METHODS AND RESULTS: Twelve patients with pulmonary hypertension (seven primary and five secondary) were studied. All patients had a pulmonary artery balloon flotation catheter inserted into the proximal pulmonary artery and radial arterial line. Prostacyclin was nebulized with 81. min–1 of oxygen and administered in doses increasing from 15 to 50 ng. kg–1. min–1 via a facemask. Eight of these patients also received intravenous prostacyclin in doses of 1 to 5 ng.kg–1.min–1 and nitric oxide in doses of 10 to 100 ppm via a facemask. Haemodynamic measurements were taken during each treatment. In the 12 patients, nebulized prostacyclin produced a significant reduction in mean pulmonary artery pressure from 56±5 to 45±4 mmHg (P=0·0001). The pulmonary vascular resistance decreased by 38% from 964±169 to 595±116 dyne s–1.cm–5 (P=0·0001). Direct comparison with inhaled nitric oxide and intravenous prostacyclin in eight patients demonstrated that nebulized prostacyclin produced a greater fall in mean pulmonary artery pressure than the other two agents without any significant effect on systemic arterial pressure.
CONCLUSION: Nebulized prostacyclin appears to be more effective at reducing pulmonary artery pressure in patients with pulmonary hypertension when compared to intravenous prostacyclin and inhaled nitric oxide. This could have important clinical implications for the management of patients with pulmonary hypertension.
Key Words: Pulmonary hypertension • prostacyclin • nitric oxide
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Humpl, J. T. Reyes, H. Holtby, D. Stephens, and I. Adatia Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study Circulation, June 21, 2005; 111(24): 3274 - 3280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lowson Alternatives to nitric oxide Br. Med. Bull., November 5, 2004; 70(1): 119 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ray, G. J. Murphy, and L. E. Shutt Recognition and management of maternal cardiac disease in pregnancy Br. J. Anaesth., September 1, 2004; 93(3): 428 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Bildirici and J B. Shumway Intravenous and Inhaled Epoprostenol for Primary Pulmonary Hypertension During Pregnancy and Delivery Obstet. Gynecol., May 1, 2004; 103(5): 1102 - 1105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. De Wet, D. G. Affleck, E. Jacobsohn, M. S. Avidan, H. Tymkew, L. L. Hill, P. B. Zanaboni, N. Moazami, and J. R. Smith Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1058 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Fruhwald, B. Kjellstrom, W. Perthold, N. Watzinger, R. Maier, P. A. Grandjean, and W. Klein Continuous Hemodynamic Monitoring in Pulmonary Hypertensive Patients Treated With Inhaled Iloprost Chest, July 1, 2003; 124(1): 351 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Fischer, H. V. Aken, and H. Burkle Management of Pulmonary Hypertension: Physiological and Pharmacological Considerations for Anesthesiologists Anesth. Analg., June 1, 2003; 96(6): 1603 - 1616. [Full Text] [PDF]
|
|
|
|
|
|
A. Martineau, G. Arcand, P. Couture, D. Babin, L. P. Perreault, and A. Denault Transesophageal Echocardiographic Diagnosis of Carbon Dioxide Embolism During Minimally Invasive Saphenous Vein Harvesting and Treatment with Inhaled Epoprostenol Anesth. Analg., April 1, 2003; 96(4): 962 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hache, A. Denault, S. Belisle, D. Robitaille, P. Couture, P. Sheridan, M. Pellerin, D. Babin, N. Noel, M.-C. Guertin, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 642 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Mcmillan, W L Martin, J Waugh, I Rushton, M Lewis, T Clutton-Brock, J N Townend, M D Kilby, and C Gordon Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome Lupus, June 1, 2002; 11(6): 392 - 398. [Abstract] [PDF]
|
|
|
|
|
|
A. Haraldsson, N. Kieler-Jensen, and S.-E. Ricksten The Additive Pulmonary Vasodilatory Effects of Inhaled Prostacyclin and Inhaled Milrinone in Postcardiac Surgical Patients with Pulmonary Hypertension Anesth. Analg., December 1, 2001; 93(6): 1439 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs] Can J Anesth, October 1, 2001; 48(9): 924 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]
|
|
|
|
|
|
P. Schenk, V. Petkov, C. Madl, L. Kramer, M. Kneussl, R. Ziesche, and I. Lang Aerosolized Iloprost Therapy Could Not Replace Long-term IV Epoprostenol (Prostacyclin) Administration in Severe Pulmonary Hypertension Chest, January 1, 2001; 119(1): 296 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Krasuski, J. J. Warner, A. Wang, J. K. Harrison, V. F. Tapson, and T. M. Bashore Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2204 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Schroeder, G. L. Wood, J. S. Plotkin, and P. C. Kuo Intraoperative Use of Inhaled PGI2 for Acute Pulmonary Hypertension and Right Ventricular Failure Anesth. Analg., August 1, 2000; 91(2): 291 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wensel, C. F. Opitz, R. Ewert, L. Bruch, and F. X. Kleber Effects of Iloprost Inhalation on Exercise Capacity and Ventilatory Efficiency in Patients With Primary Pulmonary Hypertension Circulation, May 23, 2000; 101(20): 2388 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group* Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial Ann Intern Med, March 21, 2000; 132(6): 435 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Fishman Epoprostenol (Prostacyclin) and Pulmonary Hypertension Ann Intern Med, March 21, 2000; 132(6): 500 - 502. [Full Text] [PDF]
|
|
|
|
 |
|
 B.M Weiss and O.M Hess Pulmonary vascular disease and pregnancy: current controversies, management strategies, and perspectives Eur. Heart J., January 2, 2000; 21(2): 104 - 115. [PDF]
|
|
|
|
 |
|
 A J Peacock Rare diseases bullet 5: Primary pulmonary hypertension Thorax, December 1, 1999; 54(12): 1107 - 1118. [Full Text]
|
|
|
|
|
|
M. Aranda, K. K. Bradford, and R. G. Pearl Combined Therapy with Inhaled Nitric Oxide and Intravenous Vasodilators During Acute and Chronic Experimental Pulmonary Hypertension Anesth. Analg., July 1, 1999; 89(1): 152 - 152. [Abstract] [Full Text] [PDF]
|
|